Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technolo...
January 05 2017 - 4:01PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering,
developing and commercializing medicines that improve outcomes for
immunocompromised patients, today announced the appointments of
Randall Lanier, PhD, as Chief Science Officer and Roy W. Ware, PhD,
MBA, as Chief Manufacturing and Technology Officer. Dr. Lanier will
continue to oversee preclinical screening programs, biology and
virology. Dr. Ware will oversee manufacturing, clinical trial
material sourcing, medicinal and process chemistry, and analytical
and pharmaceutical development. Together they will lead the
Chimerix Discovery effort.
“Over the course of their tenures at Chimerix, both Drs. Lanier
and Ware have made important contributions to our development
programs for brincidofovir and pipeline clinical candidates,” said
M. Michelle Berrey, MD, MPH, President and CEO. “We will continue
to rely on Dr. Lanier’s antiviral expertise and Dr. Ware’s
expertise in chemistry and manufacturing as we move towards the
successful commercialization of brincidofovir and advance our
pipeline research programs.”
During his tenure at Chimerix, Dr. Lanier has led teams that
designed successful studies of brincidofovir for smallpox,
characterized the resistance/activity profile of brincidofovir for
multiple viruses, and explored the potential of the Chimerix
chemical library to address unmet medical needs. Recently these
efforts led to the identification of a clinical candidate, CMX521,
for norovirus, the leading cause of viral gastroenteritis
worldwide. Dr. Lanier has nearly 25 years of experience in the
discovery and development of antivirals; he has focused much of his
career on understanding the activity, mechanism, and resistance
profiles of nucleoside analogs used for prevention and treatment of
viral disease caused by HIV, CMV, adenovirus and poxviruses. Prior
to joining Chimerix in 2007, Dr. Lanier held positions of
increasing leadership at Burroughs Wellcome, GlaxoWellcome, and
GlaxoSmithKline, where he supervised a clinical virology/immunology
laboratory, led teams for drug discovery and licensing opportunity
evaluation, served as the clinical virologist on several projects
(three approved NDAs), and supported product differentiation and
post-marketing activities. Dr. Lanier holds a B.A. in Biology from
New College in Sarasota, Florida, and a PhD in Cellular and
Molecular Biology from the University of Texas Health Science
Center in San Antonio, Texas.
In his previous position as Vice President, Chemistry at
Chimerix, Dr. Ware led the chemistry effort for discovery and
development programs, including structure/activity evaluation,
chemical process development, and manufacturing of CMX521. He also
contributed to the patent programs for brincidofovir, securing a
patent extension to 2034, and CMX157 (licensed to ContraVir),
securing a patent extension to 2033. Prior to joining Chimerix, Dr.
Ware held multiple positions in research including as a research
scientist at PharmaCore, Inc.; as a consultant to Scynexis, Inc.
working in chemical process development and cGMP synthesis; and
leading a team of medicinal chemists working on preclinical
oncology and malaria programs, as well as contributing to the
expansion of patent coverage for the proteome mining technology at
Serenex, Inc. Dr. Ware also worked in the area of drug addiction
therapy as a postdoctoral researcher at the Research Triangle
Institute. Dr. Ware received his B.A. in Chemistry from the
University of North Carolina at Greensboro, his PhD in Chemistry
from Wake Forest University, and his M.B.A. from the Kenan-Flagler
Business School at the University of North Carolina at Chapel
Hill.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to
discovering, developing and commercializing medicines that improve
outcomes for immunocompromised patients. Chimerix's proprietary
lipid conjugate technology has produced brincidofovir (BCV,
CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals;
and earlier-stage clinical candidates. Chimerix recently
announced a new clinical candidate, CMX521, for the treatment
and/or prevention of norovirus. For further information, please
visit Chimerix's website, www.chimerix.com.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the possibility that there may not be a viable continued
development path for brincidofovir, that FDA and other
regulatory authorities may not approve brincidofovir or
brincidofovir-based regimens, and that marketing approvals, if
granted, may have significant limitations on their use. As a
result, brincidofovir may never be successfully commercialized. In
addition, Chimerix may be unable to file for regulatory
approval for brincidofovir with other regulatory authorities. These
risks, uncertainties and other factors could cause actual results
to differ materially from those expressed or implied by such
forward-looking statements. Risks are described more fully in the
Company’s filings with the Securities and Exchange Commission,
including without limitation the Company’s most recent Quarterly
Report on Form 10-Q and other documents subsequently filed with or
furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this Current Report on Form
8-K speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
CONTACT:
Investor Relations:
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
Will@sternir.com
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com
413-478-2003
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024